Widely used Trivy scanner compromised in ongoing supply-chain attack

Hackers have compromised virtually all versions of Aqua Security’s widely used Trivy vulnerability scanner in an ongoing ...

Ultralytics Debuts Ultralytics Platform: The Definitive Way to Annotate, Train, and Deploy Vision AI

Ultralytics, the company behind the YOLO family of object detection models, today introduced Ultralytics Platform, a comprehensive end-to-end vision AI platform featuring powerful SAM-powered smart ...
The Hacker News

⚡ Weekly Recap: Qualcomm 0-Day, iOS Exploit Chains, AirSnitch Attack & Vibe-Coded Malware

Your weekly cybersecurity roundup covering the latest threats, exploits, vulnerabilities, and security news you need to know.

The Capture season three: experts in facial recognition and AI decipher the fact from the fiction

It is not feasible, nor indeed ethical, to run a facial recognition system against all images on the internet.
BioSpace

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth ...
Seeking Alpha

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma ...

MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI ® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & ...
IEEE

Face Mask Detection for Real-Time Monitoring Using MobileNetV2: A Bias-Aware, Cross-Validated, and Efficient Deep Learning Framework

The COVID-19 pandemic has created unprecedented challenges for global public health systems, intensifying the need for scalable strategies to reduce airborne disease transmission. Among the most ...
Seeking Alpha

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Phase 3 AQUILA study showed DARZALEX FASPRO ® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...